Company: Glycostem Therapeutics B.V.
Job title: CMO
Bringing Allogeneic NK cells into Clinical Trials for AML 2:30 pm
Providing an update on oNKord®, an allogeneic NK cell product, in the WiNK AML trial Understanding the safety aspects of the clinical trial for the use of allogeneic NK cells Understanding the role of conditioning chemotherapy for therapeutic efficacyRead more
day: Day Two